83 related articles for article (PubMed ID: 23733133)
1. Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer.
Ikeda Y; Oda K; Hiraike-Wada O; Koso T; Miyasaka A; Kashiyama T; Tanikawa M; Sone K; Nagasaka K; Maeda D; Kawana K; Nakagawa S; Fukayama M; Tetsu O; Fujii T; Yano T; Kozuma S
Oncol Rep; 2013 Aug; 30(2):584-8. PubMed ID: 23733133
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas.
Xu J; Lin DI
PLoS One; 2018; 13(7):e0199688. PubMed ID: 29969496
[TBL] [Abstract][Full Text] [Related]
3. Expression of the cell-cycle regulatory proteins (pRb, cyclin D1, p16INK4A and cdk4) in human endometrial cancer: correlation with clinicopathological features.
Semczuk A; Miturski R; Skomra D; Jakowicki JA
Arch Gynecol Obstet; 2004 Jan; 269(2):104-10. PubMed ID: 14648178
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 gene (CCND1) mutations in endometrial cancer.
Moreno-Bueno G; Rodríguez-Perales S; Sánchez-Estévez C; Hardisson D; Sarrió D; Prat J; Cigudosa JC; Matias-Guiu X; Palacios J
Oncogene; 2003 Sep; 22(38):6115-8. PubMed ID: 12955092
[TBL] [Abstract][Full Text] [Related]
5. Molecular alterations associated with cyclin D1 overexpression in endometrial cancer.
Moreno-Bueno G; Rodríguez-Perales S; Sánchez-Estévez C; Marcos R; Hardisson D; Cigudosa JC; Palacios J
Int J Cancer; 2004 Jun; 110(2):194-200. PubMed ID: 15069681
[TBL] [Abstract][Full Text] [Related]
6. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein.
Paramio JM; Navarro M; Segrelles C; Gómez-Casero E; Jorcano JL
Oncogene; 1999 Dec; 18(52):7462-8. PubMed ID: 10602505
[TBL] [Abstract][Full Text] [Related]
7. [Topics on gene abnormality in endometrial cancer].
Shiozawa T; Konishi I
Nihon Rinsho; 2004 Oct; 62 Suppl 10():259-63. PubMed ID: 15535247
[No Abstract] [Full Text] [Related]
8. Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity.
Jares P; Campo E; Pinyol M; Bosch F; Miquel R; Fernandez PL; Sanchez-Beato M; Soler F; Perez-Losada A; Nayach I; Mallofré C; Piris MA; Montserrat E; Cardesa A
Am J Pathol; 1996 May; 148(5):1591-600. PubMed ID: 8623927
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
Velasco A; Bussaglia E; Pallares J; Dolcet X; Llobet D; Encinas M; Llecha N; Palacios J; Prat J; Matias-Guiu X
Hum Pathol; 2006 Nov; 37(11):1465-72. PubMed ID: 16949921
[TBL] [Abstract][Full Text] [Related]
11. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin D1.
Xu YY; Wu HJ; Ma HD; Xu LP; Huo Y; Yin LR
FEBS J; 2013 Aug; 280(16):3768-79. PubMed ID: 23731275
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
[TBL] [Abstract][Full Text] [Related]
14. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.
Oda K; Stokoe D; Taketani Y; McCormick F
Cancer Res; 2005 Dec; 65(23):10669-73. PubMed ID: 16322209
[TBL] [Abstract][Full Text] [Related]
15. ras activity and cyclin D1 expression: an essential mechanism of mouse skin tumor development.
Rodriguez-Puebla ML; Robles AI; Conti CJ
Mol Carcinog; 1999 Jan; 24(1):1-6. PubMed ID: 10029404
[TBL] [Abstract][Full Text] [Related]
16. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Kurose K; Zhou XP; Araki T; Cannistra SA; Maher ER; Eng C
Am J Pathol; 2001 Jun; 158(6):2097-106. PubMed ID: 11395387
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells.
Kim CJ; Nishi K; Isono T; Okuyama Y; Tambe Y; Okada Y; Inoue H
Mol Carcinog; 2009 Oct; 48(10):953-64. PubMed ID: 19415719
[TBL] [Abstract][Full Text] [Related]
18. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
19. Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1.
Benzeno S; Lu F; Guo M; Barbash O; Zhang F; Herman JG; Klein PS; Rustgi A; Diehl JA
Oncogene; 2006 Oct; 25(47):6291-303. PubMed ID: 16732330
[TBL] [Abstract][Full Text] [Related]
20. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines.
Sartor M; Steingrimsdottir H; Elamin F; Gäken J; Warnakulasuriya S; Partridge M; Thakker N; Johnson NW; Tavassoli M
Br J Cancer; 1999 Apr; 80(1-2):79-86. PubMed ID: 10389982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
